Kevin F. Staveley-O'Carroll Department of Surgery University of Missouri-Columbia Biography Publications Institution JoVE Articles Kevin F. Staveley-O'Carroll has not added a biography. If you are Kevin F. Staveley-O'Carroll and would like to personalize this page please email our Author Liaison for assistance. Publications PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer Cancers. Jun, 2019 | Pubmed ID: 31212653 Targeted and Immune-Based Therapies for Hepatocellular Carcinoma Gastroenterology. 01, 2019 | Pubmed ID: 30287171 Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer Journal of Immunology Research and Therapy. 2018 | Pubmed ID: 30123861 Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice Gastroenterology. 03, 2018 | Pubmed ID: 29408569 Sunitinib Represses Regulatory T Cells to Overcome Immunotolerance in a Murine Model of Hepatocellular Cancer Oncoimmunology. 2017 | Pubmed ID: 29296523 Successful Chemoimmunotherapy Against Hepatocellular Cancer in a Novel Murine Model Journal of Hepatology. Jan, 2017 | Pubmed ID: 27520877 Perioperative Circulating Tumor Cell Detection: Current Perspectives Cancer Biology & Therapy. 08, 2016 | Pubmed ID: 27045201 A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer Pharmaceuticals (Basel, Switzerland). Mar, 2016 | Pubmed ID: 27023566 Um modelo de camundongo de câncer hepatocelular induzido por hepatócitos oncogênico, decorrente do ajuste da inflamação e fibrose hepática Xiaoqiang Qi*1,2,3, Emily Schepers*1,2, Diego Avella1,2, Eric T. Kimchi1,2, Jussuf T. Kaifi1,2, Kevin F. Staveley-O'Carroll1,2, Guangfu Li1,2,3 1Department of Surgery, University of Missouri-Columbia, 2Ellis Fischel Cancer Center, University of Missouri-Columbia, 3Molecular Microbiology and Immunology, University of Missouri-Columbia JoVE 59368 Cancer Research
Um modelo de camundongo de câncer hepatocelular induzido por hepatócitos oncogênico, decorrente do ajuste da inflamação e fibrose hepática Xiaoqiang Qi*1,2,3, Emily Schepers*1,2, Diego Avella1,2, Eric T. Kimchi1,2, Jussuf T. Kaifi1,2, Kevin F. Staveley-O'Carroll1,2, Guangfu Li1,2,3 1Department of Surgery, University of Missouri-Columbia, 2Ellis Fischel Cancer Center, University of Missouri-Columbia, 3Molecular Microbiology and Immunology, University of Missouri-Columbia JoVE 59368 Cancer Research
